About

K Pharma emerged as a spin-off company from Keio University School of Medicine, dedicated to transforming pioneering research by Professor Hideyuki Okano (Department of Physiology) and Professor Masaya Nakamura (Department of Orthopaedic Surgery) into practical applications. Our unwavering commitment to pushing the boundaries of healthcare has led us to specialize in medical treatments involving nerve regeneration and iPS drug discovery. We pride ourselves on maintaining a close partnership with Keio University School of Medicine, with recent strides in iPS drug discovery culminating in the successful completion of the first phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) treatment. With the phase 3 study looming, we are excited to continue our exploration of iPS drug discovery to tackle other intractable neurological diseases. Our collaboration extends to regenerative medicine, where we are currently in preparing sponsor-initiated clinical trials for the treatment of subacute spinal cord injury. Looking ahead, we plan to broaden the scope of regenerative medicine to encompass treatments for chronic spinal cord injury and cerebral infarctions. About K Pharma, Inc. K Pharma is a publicly traded company (TSE) that originated from Keio University School of Medicine and was established in November 2016. Leveraging human iPS cell technology discovered by Professor Shinya Yamanaka of Kyoto University in 2007, K Pharma is engaged in regenerative medicine business for conditions such as spinal cord injury and stroke, as well as “iPS drug discovery” business targeting intractable neurological disorders. K Pharma is committed to addressing unmet medical needs worldwide and contribution. K Pharma is a publicly traded company (TSE) that originated from Keio University School of Medicine and was established in November 2016. Leveraging human iPS cell technology discovered by Professor Shinya Yamanaka of Kyoto University in 2007, K Pharma is engaged in regenerative medicine business for conditions such as spinal cord injury and stroke, as well as “iPS drug discovery” business targeting intractable neurological disorders. K Pharma is committed to addressing unmet medical needs worldwide and contribution.